Datapoint

Datapoint: Centene Takes on Major Medicare Expansion for 2022

October 12, 2021

Centene Corp. on Oct. 4 said it will expand its Medicare Advantage market’s geographic footprint by 26% in 2021, offering products in 1,575 counties across 36 states. Centene currently serves 1,208,486 MA members across its AllWell, Fidelis, Health Net and WellCare brands. In September, the company announced it is consolidating all of its MA products under the WellCare brand.

Centene Corp. on Oct. 4 said it will expand its Medicare Advantage market’s geographic footprint by 26% in 2021, offering products in 1,575 counties across 36 states. Centene currently serves 1,208,486 MA members across its AllWell, Fidelis, Health Net and WellCare brands. In September, the company announced it is consolidating all of its MA products under the WellCare brand.

Source: AIS’s Directory of Health Plans

Datapoint: Humana Unveils 2022 MA Plans

October 11, 2021

Humana Inc. will offer 72 new Medicare Advantage plans in the 2022 plan year, expanding to “hundreds” of new counties according to an Oct. 1 press release from the insurer. The insurer has enhanced its benefits package, offering $0 telehealth visits to all MA-PD members, and no cost benefits to members with a COVID diagnosis. With 4,889,718, Humana is the second-largest MA insurer in the U.S., behind UnitedHealthcare.

Humana Inc. will offer 72 new Medicare Advantage plans in the 2022 plan year, expanding to “hundreds” of new counties according to an Oct. 1 press release from the insurer. The insurer has enhanced its benefits package, offering $0 telehealth visits to all MA-PD members, and no cost benefits to members with a COVID diagnosis. With 4,889,718, Humana is the second-largest MA insurer in the U.S., behind UnitedHealthcare.

Source: AIS’s Directory of Health Plans

Datapoint: FDA Approves AbbVie’s Qulipta in Migraine Prevention

October 7, 2021

The FDA on Sept. 28 approved AbbVie’s CGRP inhibitor Qulipta for the prevention of episodic migraine, with analysts already calling the drug a blockbuster-to-be. Qulipta will have to face off against Biohaven’s Nurtec ODT, the first oral CGRP inhibitor approved in the migraine space. For migraine prevention, Nurtec holds covered or better status for 77% of all insured lives under the pharmacy benefit, and is not covered for 19.2% of lives.

The FDA on Sept. 28 approved AbbVie’s CGRP inhibitor Qulipta for the prevention of episodic migraine, with analysts already calling the drug a blockbuster-to-be. Qulipta will have to face off against Biohaven’s Nurtec ODT, the first oral CGRP inhibitor approved in the migraine space. For migraine prevention, Nurtec holds covered or better status for 77% of all insured lives under the pharmacy benefit, and is not covered for 19.2% of lives.

SOURCE: MMIT Analytics, as of 10/6/21

Datapoint: Aetna Plots 2022 Medicare Expansion

October 6, 2021

CVS Health Corp.’s Aetna will expand its Medicare Advantage products to 83 new counties for the 2022 plan year, bringing its total reach to 46 states, according to an Oct. 1 press release. With this expansion, the insurer said its $0 premium options will be available to more than 80% of its service areas. Aetna currently serves 2,769,989 Medicare Advantage and 94,831 dual-eligible members nationwide.

CVS Health Corp.’s Aetna will expand its Medicare Advantage products to 83 new counties for the 2022 plan year, bringing its total reach to 46 states, according to an Oct. 1 press release. With this expansion, the insurer said its $0 premium options will be available to more than 80% of its service areas. Aetna currently serves 2,769,989 Medicare Advantage and 94,831 dual-eligible members nationwide.

Source: AIS’s Directory of Health Plans

Datapoint: Oscar Expanding to Chicago, Miami

October 5, 2021

Oscar Health will partner with health systems in the Chicago and Miami areas to expand its individual offerings to four populous counties for the 2022 plan year, according to recent press releases from the insurer. The exchange plans will offer localized services, including “Care Guides,” zero cost virtual visits and $3 prescriptions for common medications. Oscar currently serves 467,070 members through the Affordable Care Act exchanges, with Florida being its largest market at 245,000 lives.

Oscar Health will partner with health systems in the Chicago and Miami areas to expand its individual offerings to four populous counties for the 2022 plan year, according to recent press releases from the insurer. The exchange plans will offer localized services, including “Care Guides,” zero cost virtual visits and $3 prescriptions for common medications. Oscar currently serves 467,070 members through the Affordable Care Act exchanges, with Florida being its largest market at 245,000 lives.

Source: AIS’s Directory of Health Plans

Datapoint: Tivdak Scores FDA Nod for Cervical Cancer

October 4, 2021

The FDA on Sept. 20 granted an accelerated approval to Seagen Inc. and Genmab A/S’s Tivdak for the treatment of recurrent or metastatic cervical cancer that has continued to progress following chemotherapy. The drug is the first antibody-drug conjugate approved for cervical cancer. Among the most advantaged cervical cancer therapies are Roche’s Avastin, which holds covered or better status for 89% of all insured lives under the medical benefit, Amgen’s Mvasi (a biosimilar to Avastin, also 89%) and Merck’s Keytruda (85%).

The FDA on Sept. 20 granted an accelerated approval to Seagen Inc. and Genmab A/S’s Tivdak for the treatment of recurrent or metastatic cervical cancer that has continued to progress following chemotherapy. The drug is the first antibody-drug conjugate approved for cervical cancer. Among the most advantaged cervical cancer therapies are Roche’s Avastin, which holds covered or better status for 89% of all insured lives under the medical benefit, Amgen’s Mvasi (a biosimilar to Avastin, also 89%) and Merck’s Keytruda (85%).

SOURCE: MMIT Analytics, as of 9/23/21